New hydrogel injection for knee osteoarthritis is offering patients a return to mobility without surgery

Arthrosamid® was created by Contura International Ltd (international manufacturers of therapeutic hydrogels) and fulfils an unmet clinical need for an effective, long-acting, safe, and minimally invasive treatment to help alleviate pain associated with knee osteoarthritis (OA).

With approximately 8.5 million people in the UK (around 1/5 people aged over 45 in England) being affected by OA, this treatment has the potential to change the pathway for managing OA, as current treatments involve invasive knee replacement surgery or are not as effective long-term.

A 6ml dose (2.5% cross-linked polyacrylamide and 97.5% non-pyrogenic water) is injected into the intra-articular cavity. The hydrogel integrates into the synovial tissue of the inner joint capsule and thickens the synovial membrane. Because the hydrogel is non-absorbable, non-biodegradable, and non-migratory, it provides durable cushioning of the inner capsular tissue, helps reduce pain and joint stiffness, and improves the overall function of the knee within days.

Unlike other types of intra-articular injections, Arthrosamid® is physically different as it becomes an integrated part of the soft synovial tissue in the joint capsule. This enables it to help relieve the symptoms of OA for a substantially longer time than older generation OA treatments.

Interested to read more?  Click here to read the full article  

If you’re suffering from knee osteoarthritis or are interested in seeing any of our specialists, please leave an enquiry via the button below.